The US National Institutes of Health (NIH) and Foundation for the NIH (FNIH) have launched a collaboration between industry and Federal agencies to tackle the coronavirus pandemic.
NIH Director Francis S. Collins said:
“We need to bring the full power of the biomedical research enterprise to bear on this crisis. Now is the time to come together with unassailable objectivity to swiftly advance the development of the most promising vaccine and therapeutic candidates that can help end the COVID-19 global pandemic.
The collaboration, known as Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV), will bring together the Health and Human Services Office of the Assistant Secretary for Preparedness and Response, the Centers for Disease Control and Prevention (CDC), the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Joining these bodies are “more than a dozen leading biopharmaceutical companies”.
The ACTIV partners will bring together their expertise and funding around treatments and vaccines for the virus, as well as infrastructure support.
Mikael Dolsten, Chief Scientific Officer of Pfizer, said:
“Battling the COVID-19 pandemic is far too great a challenge for any one company or institution to solve alone… We are seeing an unprecedented level of collaboration across the innovation ecosystem to address this global health crisis, and this potentially powerful NIH initiative may allow us to further accelerate the delivery of much needed therapies to patients around the world.”
Find out more about ACTIV and its workstreams here.